Key points are not available for this paper at this time.
Introduction 8 237 54.9% men), there were 1,429 coronary heart disease, 985 heart failure, 595 stroke and 1,904 deaths. NAFLD was associated with an increased risk of coronary heart disease (HR: 1.65, 95% CI: 1.22-2.23), and a high FLI (quartile 4) was linked to a 110% higher risk of heart failure (95% CI: 1.52-2.90), a 91% higher risk of all-cause mortality (95% CI: 1.54-2.39), and an 83% higher risk of cancer mortality (95% CI: 1.30-2.59). Participants at high risk for fibrosis had a significantly higher risk of all-cause mortality than those at low risk for fibrosis (BARD, HR: 1.65, 95% CI: 1.14-2.38; FIB-4, HR: 1.68, 95% CI: 1.37-2.06; NFS, HR: 1.49, 95% CI: 1.29-1.73). A high risk for fibrosis determined by the NFS and FIB-4 was also linked with higher risks of mortality from CVD (HR: 1.59, 95% CI: 1.17-2.15) and cancer (HR: 1.53, 95% CI: 1.09-2.16), respectively. Conclusion: These findings suggest that NAFLD and liver fibrosis are associated with elevated risks of major CVD, all-cause and cause-specific mortality in individuals with T2DM. Assessing individuals with T2DM for the presence and progression of NAFLD during clinical consultations is recommended. Disclosure S. Xu: None. Q. You: None. L. Liu: None. Funding This work was supported by the Key project of Hubei Natural Science Foundation Innovation and Development Joint Fund (Grant number 2023AFD031), and the Science and Technology Research Key Project of Education Department of Hubei Province China (Grant number D20212602).
Xu et al. (Fri,) studied this question.